GSK article the times24 Jun 2021 00:46
After the separation the remaining business will have a lower leverage ratio of less than two times. This, combined with an expectation of stronger cash flow generation, exceeding £10 billion by 2026, is designed to give management more firepower and flexibility for investments and product launches. These will include more bolt-on and licensing deals not dissimilar to this month’s $2.1 billion collaboration on an experimental cancer drug with iTeos Therapeutics, a Nasdaq-listed biotech company